Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization.
We identified patients who experienced ovarian hyperstimulation syndrome (OHSS) (n = 16) and compared their baseline pretreatment levels of müllerian-inhibiting substance (MIS) to age- and weight-matched patients with normal responses to gonadotropins (n = 14). Baseline serum MIS in patients with OHSS were sixfold higher than those seen in normal controls (3.62 +/- 0.87 vs. 0.63 +/- 0.09 ng/mL; P=.0036), indicating that MIS could potentially serve as a useful marker for identifying patients at risk for OHSS.
Nakhuda
Gary S
GS
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York, USA. gsn16@columbia.edu
Chu
Micheline C
MC
Wang
Jeff G
JG
Sauer
Mark V
MV
Lobo
Rogerio A
RA
D000328:Adult; D054304:Anti-Mullerian Hormone; D015415:Biomarkers / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood* / Q000175:diagnosis / Q000209:etiology*; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D013735:Testicular Hormones / Q000097:blood*
D015415:Biomarkers; D006023:Glycoproteins; D013735:Testicular Hormones; D054304:Anti-Mullerian Hormone